Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
approved tags : China save search
Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China
Published: 2024-03-19 (Crawled : 12:00) - globenewswire.com
CMND | $1.19 14K
|
n/a
|
| O: 1.54%
H: 1.52%
C: -2.27%
patent granted approval treatment china
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
Published: 2024-02-26 (Crawled : 00:00) - biospace.com/
KZR | $0.8372 1.85% 400K
|
Health Technology
|
| O: 1.09%
H: 3.74%
C: -1.52%
lupus life approval sciences trial china
Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China
Published: 2024-02-05 (Crawled : 13:00) - globenewswire.com
CMND | $1.19 14K
|
n/a
|
| O: 4.92%
H: 9.38%
C: -8.59%
patent approval treatment china
Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
Published: 2023-12-21 (Crawled : 00:00) - biospace.com/
TAK | News | $13.38 0.15% 1.3M
|
Health Technology
|
| O: 2.05%
H: 0.29%
C: 0.0%
livtencity approval cytomegalovirus treatment china
Calliditas' partner Everest Medicines announces China NMPA's approval of Nefecon® for the treatment of primary IgA nephropathy
Published: 2023-11-24 (Crawled : 09:00) - biospace.com/
CALT | $18.0825 1.5K
|
Health Technology
|
| O: 3.31%
H: 0.81%
C: 0.81%
nefecon nephropathy approval treatment china
Everest Medicines Announces China NMPA's Approval of Nefecon® for the Treatment of Primary IgA Nephropathy in Adult Patients
Published: 2023-11-24 (Crawled : 05:00) - prnewswire.com
CALT | $18.0825 1.5K
|
Health Technology
|
| O: 3.31%
H: 0.81%
C: 0.81%
nefecon nephropathy approval treatment china
Establishment Labs Announces National Medical Products Administration Approval for Motiva Implants in China
Published: 2023-11-09 (Crawled : 14:00) - biospace.com/
ESTA | $49.37 2.28% 160K
|
Health Technology
|
| O: 5.51%
H: 2.38%
C: -14.04%
approval medical china
CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA
Published: 2023-11-08 (Crawled : 13:00) - biospace.com/
CASI | $2.42 -0.41% 10K
|
Health Technology
|
| O: 0.0%
H: 5.07%
C: -0.97%
cnct19 approval pharmaceuticals china market
Bionano Announces Third OEM Partner has Received China NMPA Approval for DNA Isolation Products for IVD Use of OGM
Published: 2023-09-21 (Crawled : 12:30) - globenewswire.com
BNGO | $0.781 2.68% 640K
|
Health Technology
|
| O: -1.33%
H: 5.68%
C: 0.68%
approval dna china
Bionano Announces Second OEM Partner has Received China NMPA Approval for DNA Extraction and Labeling Products for IVD Use of OGM in Reproductive Health
Published: 2023-08-28 (Crawled : 12:00) - globenewswire.com
BNGO | $0.781 2.68% 640K
|
Health Technology
|
| O: 0.32%
H: 0.65%
C: -2.59%
health approval dna china
FINRA Announces Approval for Corporate Name Change From China Infrastructure Construction Corp. to Cannabis Bioscience International Holdings and Ticker Symbol Change from CHNC to CBIH
Published: 2023-08-21 (Crawled : 13:00) - globenewswire.com
CHNC | $0.0004 575.0% 860K
|
n/a
| Email alert
Add to watchlist
cannabis change approval construction bioscience international china
argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
Published: 2023-06-30 (Crawled : 13:20) - globenewswire.com
ZLAB | $15.24 1.67% 320K
|
Health Technology
|
| O: 0.19%
H: 5.92%
C: 4.64%
ARGX | $376.62 2.13% 240K
|
Health Technology
|
| O: 0.91%
H: 1.21%
C: 0.85%
vyvgart approval china
Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
Published: 2023-06-30 (Crawled : 13:00) - globenewswire.com
ZLAB | $15.24 1.67% 320K
|
Health Technology
|
| O: 0.19%
H: 5.92%
C: 4.64%
ARGX | $376.62 2.13% 240K
|
Health Technology
|
| O: 0.91%
H: 1.21%
C: 0.85%
vyvgart approval china
Medivir's patent application for fostrox approved in China
Published: 2023-06-19 (Crawled : 09:00) - biospace.com/
IGMS | $7.705 14.15% 260K
|
Health Technology
| Email alert
Add to watchlist
patent approved application china
CANbridge Announces Marketing Approval of CAN108 (迈芮倍®/LIVMARLI®) in China for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
Published: 2023-06-02 (Crawled : 09:00) - biospace.com/
MIRM | $24.905 3.04% 180K
|
Health Technology
|
| O: 0.38%
H: 1.6%
C: 0.46%
can108 livmarli pruritus approval treatment china
Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China
Published: 2023-06-01 (Crawled : 10:00) - globenewswire.com
AMRN | News | $0.8888 2.67% 560K
|
Health Technology
|
| O: 3.42%
H: 4.96%
C: 0.0%
vascepa approval china
Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate clinical trial with lanifibranor in China
Published: 2023-05-25 (Crawled : 20:00) - globenewswire.com
IVA | $3.3 3.2K
|
Health Technology
|
| O: 2.78%
H: 0.67%
C: -2.71%
approval trial china
LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in the Macau Special Administrative Region (SAR) of China
Published: 2023-05-11 (Crawled : 11:00) - globenewswire.com
LIAN | $4.92 0.41% 0.41% 410K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 10.09%
C: 0.92%
camzyos approval china
The China NMPA Approves TYVYT® (sintilimab injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-mutated Non-squamous NSCLC who Progressed after EGFR-TKI Therapy
Published: 2023-05-10 (Crawled : 00:00) - prnewswire.com
LLY | News | $744.47 1.8% 1M
|
Health Technology
|
| O: -0.54%
H: 2.89%
C: 2.31%
SNY | News | $47.72 1.21% 1.1M
|
Health Technology
|
| O: -1.75%
H: 0.0%
C: 0.0%
INCY | $52.02 0.19% 1.2M
|
Health Technology
|
| O: 0.29%
H: 0.07%
C: -1.6%
tyvyt china therapy
Trevena Announces Approval of OLINVYK in China
Published: 2023-05-08 (Crawled : 11:00) - globenewswire.com
TRVN | $0.375 1.3% 140K
|
Health Technology
|
| O: 23.32%
H: 322.19%
C: 300.31%
approval olinvyk china
Gainers vs Losers
| 86% | 14% |
Top 10 Gainers
MTTR | News M | $4.56 162.07% 21M
|
AGBA | $2.74 119.2% 52M
|
Finance
CZOO | $9.07 81.76% 22M
|
EDBL | News | $6.56 74.47% 1.8M
|
MTC | $2.21 41.67% 5.6M
|
Technology Services
OPRT | News | $3.12 38.67% 11M
|
Finance
PALI | $6.59 33.67% 23M
|
Manufacturing
VNRX | $0.7989 33.15% 3.2M
|
Health Technology
BTCM | $3.51 30.0% 730K
|
Arts, Entertainment, and Recrea...
MLEC | $1.81 29.29% 2.8M
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.